AR 623

Drug Profile

AR 623

Alternative Names: All-trans-retinoic acid; ATRA-IV; Atragen; LipoATRA; Tretinoin LF; Tretinoin liposomal

Latest Information Update: 21 Feb 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Antigenics
  • Developer Agenus; Antigenics
  • Class Antineoplastics; Keratolytics; Retinoids
  • Mechanism of Action Protein synthesis inhibitors; Retinoic acid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Acute promyelocytic leukaemia; Bladder cancer; Cancer; Kaposi's sarcoma; Non-Hodgkin's lymphoma; Prostate cancer; Renal cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 06 Jan 2011 Antigenics is now called Agenus
  • 04 Oct 2006 Discontinued - Phase-II for Acute myeloid leukaemia in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top